These findings illustrate that allelic ratio obtained by our next generation sequencing assay reliably classifies the vast majority of FLT3-internal tandem duplications, which is an important consideration in light of current guidelines for the prognosis and management of FLT3-internal tandem duplication-positive acute myeloid leukemia [10, 11]. This evidence concerns the gene FLT3 and acute myeloid leukemia.